Laboratory of Applied Biochemistry, Division of Biotechnology Research and Review III, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administrations, Silver Spring, MD, 20993, USA.
Division of Biotechnology Research and Review II, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administrations, Silver Spring, MD, 20993, USA.
Pharm Res. 2021 Nov;38(11):1961-1975. doi: 10.1007/s11095-021-03125-6. Epub 2021 Nov 29.
Polysorbate excipients are commonly used as surfactants to stabilize therapeutic proteins in formulations. Degradation of polysorbates could lead to particle formation and instability of the drug formulation. We investigated how the fatty acid composition of polysorbate 80 impacts the degradation profile, particle formation, and product stability under stress conditions.
Two polysorbate 80-containing therapeutic protein formulations were reformulated with either Polysorbate 80 NF synthesized from a fatty acid mixture that contains mainly oleic acid (≥58%) or a version of polysorbate 80 synthesized with high oleic acid (>98%). Stress conditions, including high temperature and esterase spiking, were applied and changes to both the polysorbate and the therapeutic protein product were investigated for stability, purity, innate immune response and biological activity.
The addition of esterase and storage at 37°C led to significant hydrolysis of the polysorbate and increases in sub-visible particle formation for both polysorbates tested. The fatty acid composition of polysorbate 80 did not directly alter the stability profile of either therapeutic protein as measured by size exclusion chromatography, or significantly impact innate immune response or biological activity. However, formulations with Polysorbate 80 NF showed greater propensity for sub-visible particle formation under stress conditions.
These results suggest that composition of fatty acids in polysorbate 80 may be a promoter for sub-visible particulate formation under the stress conditions tested but may not impact protein aggregation or biological activity.
聚山梨酯赋形剂通常用作表面活性剂,以稳定制剂中的治疗性蛋白质。聚山梨酯的降解可能导致颗粒形成和药物制剂的不稳定性。我们研究了聚山梨酯 80 的脂肪酸组成如何影响降解谱、颗粒形成以及在应激条件下的产品稳定性。
将两种含有聚山梨酯 80 的治疗性蛋白质制剂用以下两种方法进行重新配方:一种是用主要含有油酸(≥58%)的脂肪酸混合物合成的非专利聚山梨酯 80(Polysorbate 80 NF);另一种是用高油酸(>98%)合成的聚山梨酯 80。施加了包括高温和酯酶加标在内的应激条件,并研究了聚山梨酯和治疗性蛋白质产品的变化,以评估其稳定性、纯度、固有免疫反应和生物学活性。
酯酶的添加和在 37°C 下储存导致两种测试的聚山梨酯发生显著水解,并导致亚可见颗粒形成增加。聚山梨酯 80 的脂肪酸组成并没有直接改变大小排阻色谱法测量的两种治疗性蛋白质的稳定性谱,也没有显著影响固有免疫反应或生物学活性。然而,在应激条件下,含有 Polysorbate 80 NF 的制剂表现出更大的亚可见颗粒形成倾向。
这些结果表明,聚山梨酯 80 中脂肪酸的组成可能是在测试的应激条件下导致亚可见颗粒形成的促进因素,但可能不会影响蛋白质聚集或生物学活性。